Mitochondria-targeted antioxidant MitoQ ameliorates experimental mouse colitis by suppressing NLRP3 inflammasome-mediated inflammatory cytokines

BMC Medicine

Volumn 11, Issue 1, 2013, Pages

  Dashdorj, Amarjargal ^a   KR, Jyothi ^a   Lim, Sangbin ^a   Jo, Ara ^a   Nguyen, Minh N ^a   Ha, Joohun ^a   Yoon, Kyung Sik ^a   Kim, Hyo J ^a   Park, Jae Hoon ^a   Murphy, Michael P ^b   Kim, Sung S ^a  

^a Kyung Hee University Hospital   (South Korea)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Dextran sulfate sodium; Interleukin 1 beta; Interleukin 18; MitoQ; NLRP 3 inflammasome; Reactive oxygen species

Indexed keywords

ANTIOXIDANT; CRYOPYRIN; INTERLEUKIN 18; INTERLEUKIN 1BETA; MITOQ; REACTIVE OXYGEN METABOLITE; UBIQUINONE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL ARTICLE; COLITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN CELL; MALE; MITOCHONDRION; MOUSE; NONHUMAN; OXIDATIVE STRESS; THERAPY EFFECT;

ANIMALS; ANTIOXIDANTS; CARRIER PROTEINS; CELLS, CULTURED; COLITIS; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; INFLAMMASOMES; INFLAMMATION MEDIATORS; MALE; MICE; MICE, INBRED BALB C; MITOCHONDRIA; ORGANOPHOSPHORUS COMPOUNDS; REACTIVE OXYGEN SPECIES; UBIQUINONE;

EID: 84881048250     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-11-178     Document Type: Article

References (69)

1. Kethu SR. Extraintestinal manifestations of inflammatory bowel diseases. J Clin Gastroenterology 2006, 40:467-475.
2. Guidi L, Pugliese D, Armuzzi A. Update on the management of inflammatory bowel disease: specific role of adalimumab. Clin Exp Gastroenterol 2011, 4:163-172. 3163921, 21904462.
3. Naija N, Karoui S, Serghini M, Kallel L, Boubaker J, Filali A. Management of failure of infliximab in inflammatory bowel disease. Tunis Med 2011, 89:517-521.
4. Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, Benchimol EI, Panaccione R, Ghosh S, Barkema HW, Kaplan GG. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012, 142:46-54. 10.1053/j.gastro.2011.10.001, 22001864.
5. Maloy KJ, Powrie F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature 2011, 474:298-306. 10.1038/nature10208, 21677746.
6. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009, 27:519-550. 10.1146/annurev.immunol.021908.132612, 19302047.
7. Chung Y, Chang SH, Martinez GJ, Yang XO, Nurieva R, Kang HS, Ma L, Watowich SS, Jetten AM, Tian Q, Dong C. Critical regulation of early Th17 cell differentiation by interleukin-1 signaling. Immunity 2009, 30:576-587. 10.1016/j.immuni.2009.02.007, 2705871, 19362022.
8. Clambey ET, McNamee EN, Westrich JA, Glover LE, Campbell EL, Jedlicka P, de Zoeten EF, Cambier JC, Stenmark KR, Colgan SP, Eltzschig HK. Hypoxia-inducible factor-1 alpha-dependent induction of FoxP3 drives regulatory T-cell abundance and function during inflammatory hypoxia of the mucosa. Proc Natl Acad Sci U S A 2012, 109:E2784-E2793. 10.1073/pnas.1202366109, 3478644, 22988108.
9. Ziegler SF, Buckner JH. FOXP3 and the regulation of Treg/Th17 differentiation. Microbes Infect 2009, 11:594-598. 10.1016/j.micinf.2009.04.002, 2728495, 19371792.
10. Coccia M, Harrison OJ, Schiering C, Asquith MJ, Becher B, Powrie F, Maloy KJ. IL-1 beta mediates chronic intestinal inflammation by promoting the accumulation of IL-17A secreting innate lymphoid cells and CD4 (+) Th17 cells. J Exp Med 2012, 209:1595-1609. 10.1084/jem.20111453, 3428945, 22891275.
11. Mahida YR, Wu K, Jewell DP. Enhanced production of interleukin 1-beta by mononuclear cells isolated from mucosa with active ulcerative colitis of Crohn's disease. Gut 1989, 30:835-838. 10.1136/gut.30.6.835, 1434123, 2787769.
12. McAlindon ME, Hawkey CJ, Mahida YR. Expression of interleukin 1 beta and interleukin 1 beta converting enzyme by intestinal macrophages in health and inflammatory bowel disease. Gut 1998, 42:214-219. 10.1136/gut.42.2.214, 1726995, 9536946.
13. Guimbaud R, Bertrand V, Chauvelot-Moachon L, Quartier G, Vidon N, Giroud JP, Couturier D, Chaussade S. Network of inflammatory cytokines and correlation with disease activity in ulcerative colitis. Am J Gastroenterol 1998, 93:2397-2404. 10.1111/j.1572-0241.1998.00694.x, 9860399.
14. Schoultz I, Verma D, Halfvarsson J, Törkvist L, Fredrikson M, Sjöqvist U, Lördal M, Tysk C, Lerm M, Söderkvist P, Söderholm JD. Combined polymorphisms in genes encoding the inflammasome components NALP3 and CARD8 confer susceptibility to Crohn's disease in Swedish men. Am J Gastroenterol 2009, 104:1180-1188. 10.1038/ajg.2009.29, 19319132.
15. Schroder K, Tschopp J. The inflammasome. Cell 2010, 140:821-832.
16. Bauer C, Duewell P, Mayer C, Lehr HA, Fitzgerald KA, Dauer M, Tschopp J, Endres S, Latz E, Schnurr M. Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome. Gut 2010, 59:1192-1199. 10.1136/gut.2009.197822, 20442201.
17. Bauer C, Duewell P, Lehr HA, Endres S, Schnurr M. Protective and aggravating effects of Nlrp3 inflammasome activation in IBD models: influence of genetic and environmental factors. Dig Dis 2012, 30(1):82-90.
18. Shimada K, Crother TR, Karlin J, Dagvadorj J, Chiba N, Chen S, Ramanujan VK, Wolf AJ, Vergnes L, Ojcius DM, Rentsendorj A, Vargas M, Guerrero C, Wang Y, Fitzgerald KA, Underhill DM, Town T, Arditi M. Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis. Immunity 2012, 36:401-414. 10.1016/j.immuni.2012.01.009, 3312986, 22342844.
19. Zhou R, Yazdi AS, Menu P, Tschopp J. Role for mitochondria in NLRP3 inflammasome activation. Nature 2011, 469:221-225. 10.1038/nature09663, 21124315.
20. Zhou R, Tardivel A, Thorens B, Choi I, Tschopp J. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nature Immunol 2010, 11:136-140.
21. Pavlick KP, Laroux FS, Fuseler J, Wolf RE, Gray L, Hoffman J, Grisham MB. Role of reactive metabolites of oxygen and nitrogen in inflammatory bowel disease. Free Radic Biol Med 2002, 33:311-322.
22. Beltrán B, Nos P, Dasí F, Iborra M, Bastida G, Martínez M, O'Connor JE, Sáez G, Moret I, Ponce J. Mitochondrial dysfunction, persistent oxidative damage, and catalase inhibition in immune cells of naive and treated Crohn's disease. Inflamm Bowel Dis 2010, 16:76-86. 10.1002/ibd.21027, 19637347.
23. Restivo NL, Srivastava MD, Schafer IA, Hoppel CL. Mitochondrial dysfunction in a patient with Crohn's disease: possible role in pathogenesis. J Pediatr Gastroenterol Nutr 2004, 38:534-538. 10.1097/00005176-200405000-00014, 15097444.
24. Mukhopadhyay P, Horváth B, Zsengellėr Z, Bátkai S, Cao Z, Kechrid M, Holovac E, Erdėlyi K, Tanchian G, Liaudet L, Stillman IE, Joseph J, Kalyanaraman B, Pacher P. Mitochondrial reactive oxygen species generation triggers inflammatory response and tissue injury associated with hepatic ischemia-reperfusion: therapeutic potential of mitochondrially targeted antioxidants. Free Radic Biol Med 2012, 53:1123-1138. 10.1016/j.freeradbiomed.2012.05.036, 22683818.
25. Graham D, Huynh NN, Hamilton CA, Beattie E, Smith RA, Cochemé HM, Murphy MP, Dominiczak AF. Mitochondria-targeted antioxidant MitoQ10 improves endothelial function and attenuates cardiac hypertrophy. Hypertension 2009, 54:322-328. 10.1161/HYPERTENSIONAHA.109.130351, 19581509.
26. Supinski GS, Murphy MP, Callahan LA. MitoQ administration prevents endotoxin-induced cardiac dysfunction. Am J Physiol Regul Integr Comp Physiol 2009, 297:R1095-R1102. 10.1152/ajpregu.90902.2008, 2763820, 19657095.
27. Chacko BK, Srivastava A, Johnson MS, Benavides GA, Chang MJ, Ye Y, Jhala N, Murphy MP, Kalyanaraman B, Darley-Usmar VM. The mitochondria-targeted ubiquinone MitoQ decreases ethanol-dependent micro and macro hepatosteasis. Hepatology 2011, 54:153-163. 3125473, 21520201.
28. Lowes DA, Thottakam BM, Webster NR, Murphy MP, Galley HF. The mitochondria-targeted antioxidant MitoQ protects against organ damage in a lipopolysaccharide-peptidoglycan model of sepsis. Free Radic Biol Med 2008, 45:1559-1565. 10.1016/j.freeradbiomed.2008.09.003, 18845241.
29. Gane EJ, Weilert F, Orr DW, Keogh GF, Gibson M, Lockhart MM, Frampton CM, Taylor KM, Smith RA, Murphy MP. The mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients. Liver Int 2010, 30:1019-1026. 10.1111/j.1478-3231.2010.02250.x, 20492507.
30. Lim S, Won H, Kim Y, Jang M, Jyothi KR, Kim Y, Dandona P, Ha J, Kim SS. Antioxidant enzymes induced by repeated intake of excess energy in the form of high-fat, high-carbohydrate meals are not sufficient to block oxidative stress in healthy lean individuals. Br J Nutr 2011, 106:1544-1551. 10.1017/S0007114511002091, 21676280.
31. Lee S, Tak E, Lee J, Rashid MA, Murphy MP, Ha J, Kim SS. Mitochondrial H2O2 generated from electron transport chain complex I stimulates muscle differentiation. Cell Res 2011, 21:817-834. 10.1038/cr.2011.55, 3203677, 21445095.
32. Yan Y, Kolachala V, Dalmasso G, Nguyen H, Laroui H, Sitaraman SV, Merlin D. Temporal and spatial analysis of clinical and molecular parameters in dextran sodium sulfate induced colitis. Plos One 2009, 4(6):e6073-e6080. 10.1371/journal.pone.0006073, 2698136, 19562033.
33. Yotsuya S, Shikama H, Imamura M. Efficacy of the inflammatory cell infiltration inhibitor IS-741 on colitis induced by dextran sulfate sodium in the rat. Jpn J Pharmacol 2001, 87:151-157. 10.1254/jjp.87.151, 11700014.
34. Adlam VJ, Harrison JC, Porteous CM, James AM, Smith RA, Murphy MP, Sammut IA. Targeting an antioxidant to mitochondria decreases cardiac ischemia-reperfusion injury. FASEB J 2005, 19:1088-1095. 10.1096/fj.05-3718com, 15985532.
35. Hayakawa Y, Hirata Y, Nakagawa H, Sakamoto K, Hikiba Y, Otsuka M, Ijichi H, Ikenoue T, Tateishi K, Akanuma M, Ogura K, Yoshida H, Ichijo H, Omata M, Maeda S. Apoptosis signal-regulating kinase 1 regulates colitis and colitis-associated tumorigenesis by the innate immune responses. Gastroenterology 2010, 138:1055-1067. 10.1053/j.gastro.2009.11.015, 19931259.
36. Nishiyama A, Matsui M, Iwata S, Hirota K, Masutani H, Nakamura H, Takagi Y, Sono H, Gon Y, Yodoi J. Identification of thioredoxin-binding protein -2/vitamin D3 upregulated protein 1 as a negative regulator of thioredoxin function and expression. J Biol Chem 1999, 274:21645-21650. 10.1074/jbc.274.31.21645, 10419473.
37. van de Veerdonk FL, Netea MG, Dinarello CA, Joosten LA. Inflammasome activation and IL-1 beta and IL-18 processing during infection. Trends Immunol 2011, 32:110-116. 10.1016/j.it.2011.01.003, 21333600.
38. Seidner DL, Lashner BA, Brzezinski A, Banks PL, Goldblum J, Fiocchi C, Katz J, Lichtenstein GR, Anton PA, Kam LY, Garleb KA, Demichele SJ. An oral supplement enriched with fish oil, soluble fiber, and antioxidants for corticosteroid sparing in ulcerative colitis: a randomized, controlled trial. Clin Gastroenterol Hepatol 2005, 3:358-369. 10.1016/S1542-3565(04)00672-X, 15822041.
39. Aghdassi E, Wendland BE, Steinhart AH, Wolman SL, Jeejeebhoy K, Allard JP. Antioxidant vitamin supplementation in Crohn's disease decreases oxidative stress: a randomized controlled trial. Am J Gastroenterol 2003, 98:348-353.
40. Geerling BJ, Badart-Smook A, van Deursen C, van Houwelingen AC, Russel MG, Stockbrügger RW, Brummer RJ. Nutritional supplementation with N-3 fatty acids and antioxidants in patients with Crohn's disease in remission: effects on antioxidant status and fatty acid profile. Inflamm Bowel Dis 2000, 6:77-84. 10.1097/00054725-200005000-00002, 10833065.
41. Hausmann M, Spöttl T, Andus T, Rothe G, Falk W, Schölmerich J, Herfarth H, Rogler G. Subtractive screening reveals up-regulation of NADPH oxidase expression in Crohn's disease intestinal macrophages. Clin Exp Immunol 2001, 125:48-55. 10.1046/j.1365-2249.2001.01567.x, 1906098, 11472425.
42. Szanto I, Rubbia-Brandt L, Kiss P, Steger K, Banfi B, Kovari E, Herrmann F, Hadengue A, Krause KH. Expression of NOX1, a superoxide-generating NADPH oxidase, in colon cancer and inflammatory bowel disease. J Pathol 2005, 207:164-176. 10.1002/path.1824, 16086438.
43. Söderholm JD, Olaison G, Peterson KH, Franzén LE, Lindmark T, Wirén M, Tagesson C, Sjödahl R. Augmented increase in tight junction permeability by luminal stimuli in the non-inflamed ileum of Crohn's Disease. Gut 2002, 50:307-313. 10.1136/gut.50.3.307, 1773145, 11839706.
44. Cash TP, Pan Y, Simon MC. Reactive oxygen species and cellular oxygen sensing. Free Radic Biol Med 2007, 43:1219-1225. 10.1016/j.freeradbiomed.2007.07.001, 2696222, 17893032.
45. Eltzschig HK, Carmeliet P. Hypoxia and inflammation. N Engl J Med 2011, 364:656-665. 10.1056/NEJMra0910283, 21323543.
46. Eltzschig HK, Sitkovsky MV, Robson SC. Purinergic signaling during inflammation. N Engl J Med 2013, 368:1260.
47. Shah YM, Ito S, Morimura K, Chen C, Yim SH, Haase VH, Gonzalez FJ. Hypoxia-inducible factor augments experimental colitis through a MIF-dependent inflammatory signaling cascade. Gastroenterology 2008, 134:2036-2048. 10.1053/j.gastro.2008.03.009, 2533811, 18439915.
48. Scortegagna M, Cataisson C, Martin RJ, Hicklin DJ, Schreiber RD, Yuspa SH, Arbeit JM. HIF-1alpha regulates epithelial inflammation by cell autonomous NFkB activation and paracrine stromal remodeling. Blood 2008, 111:3343-3354. 10.1182/blood-2007-10-115758, 2275004, 18199827.
49. Lluis JM, Buricchi F, Chiarugi P, Morales A, Fernandez-Checa JC. Dual role of mitochondrial reactive oxygen species in hypoxia signaling: activation of nuclear factor-{kappa}B via c-SRC and oxidant-dependent cell death. Cancer Res 2007, 67:7368-7377. 10.1158/0008-5472.CAN-07-0515, 17671207.
50. Semenza GL. Defining the role of HIF-1 in cancer biology and therapeutics. Oncogene 2010, 29:625-634. 10.1038/onc.2009.441, 2969168, 19946328.
51. Xue X, Taylor M, Anderson E, Hao C, Qu A, Greenson JK, Zimmermann EM, Gonzalez FJ, Shah YM. Hypoxia-inducible factor 2 alpha activation promotes colorectal cancer progression by dysregulation iron homeostasis. Cancer Res 2012, 72:2285-2293. 10.1158/0008-5472.CAN-11-3836, 3342485, 22419665.
52. Kaminski MM, Sauer SW, Klemke CD, Süss D, Okun JG, Krammer PH, Gülow K. Mitochondrial reactive oxygen species control T cell activation by regulating IL-2 and IL-4 expression: mechanism of ciprofloxacin-mediated immunosuppression. J Immunol 2010, 184:4827-4841. 10.4049/jimmunol.0901662, 20335530.
53. Snow BJ, Rolfe FL, Lockhart MM, Frampton CM, O'Sullivan JD, Fung V, Smith RA, Murphy MP, Taylor KM, Protect Study Group A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease modifying therapy in Parkinson's disease. Mov Disord 2010, 25:1670-1674. 10.1002/mds.23148, 20568096, Protect Study Group.
54. Pagès F, Lazar V, Berger A, Danel C, Lebel-Binay S, Zinzindohoué F, Desreumaux P, Cellier C, Thiounn N, Bellet D, Cugnenc PH, Fridman WH. Analysis of interleukin-18, interleukin-1 converting enzyme (ICE) and interleukin-18-related cytokines in Crohn's disease lesions. Eur Cytokine Netw 2001, 12:97-104.
55. Al-Sadi R, Guo S, Dokladny K, Smith MA, Ye D, Kaza A, Watterson DM, Ma TY. Mechanism of interleukin-1beta induced-increase in mouse intestinal permeability in vivo. J Interferon Cytokine Res 2012, 32:474-484. 10.1089/jir.2012.0031, 22817402.
56. Thomas TK, Will PC, Srivastava A, Wilson CL, Harbison M, Little J, Chesonis RS, Pignatello M, Schmolze D, Symington J, Kilian PL, Thompson RC. Evaluation of an interleukin-1 receptor antagonist in the rat acetic acid-induced colitis model. Agents Actions 1991, 34:187-190. 10.1007/BF01993274, 1838896.
57. Cominelli F, Nast CC, Duchini A, Lee M. Recombinant interleukin-1 receptor antagonist blocks the pro-inflammatory activity of endogenous interleukin-1 in rabbit immune colitis. Gastroenterology 1992, 103:65-71.
58. Sivakumar PV, Westrich GM, Kanaly S, Garka K, Born TL, Derry JM, Viney JL. Interleukin 18 is a primary mediator of the inflammation associated with dextran sulphate sodium induced colitis: blocking interleukin 18 attenuates intestinal damage. Gut 2002, 50:812-820. 10.1136/gut.50.6.812, 1773244, 12010883.
59. Ten Hove T, Corbaz A, Amitai H, Aloni S, Belzer I, Graber P, Drillenburg P, van Deventer SJ, Chvatchko Y, Te Velde AA. Blockade of endogenous IL-18 ameliorates TNBS-induced colitis by decreasing local TNF-alpha production in mice. Gastroenterology 2001, 121:1372-1379. 10.1053/gast.2001.29579, 11729116.
60. Siegmund B, Lehr HA, Fantuzzi G, Dinarello CA. IL-1 beta-converting enzyme (caspase-1) in intestinal inflammation. Proc Natl Acad Sci U S A 2001, 98:13249-13254. 10.1073/pnas.231473998, 60856, 11606779.
61. Loher F, Bauer C, Landauer N, Schmall K, Siegmund B, Lehr HA, Dauer M, Schoenharting M, Endres S, Eigler A. The interleukin-1 beta-converting enzyme inhibitor pralnacasan reduces dextran sulfate sodium-induced murine colitis and T helper 1 T-cell activation. J Pharmacol Exp Ther 2004, 308:583-590.
62. Meissner F, Seger RA, Moshous D, Fischer A, Reichenbach J, Zychlinsky A. Inflammasome activation in NADPH oxidase defective mononuclear phagocytes from patients with chronic granulomatous disease. Blood 2010, 116:1570-1573. 10.1182/blood-2010-01-264218, 2938844, 20495074.
63. Ni J, Chen SF, Hollander D. Effects of dextran sulphate sodium on intestinal epithelial cells and intestinal lymphocytes. Gut 1996, 39:234-241. 10.1136/gut.39.2.234, 1383305, 8991862.
64. Mizoguchi A. Animal models of inflammatory bowel disease. Prog Mol Biol Transl Sci 2012, 105:263-320.
65. Mizoguchi A, Mizoguchi E. Inflammatory bowel disease, past, present and future: lessons from animal models. J Gastroenterol 2008, 43:1-17. 10.1007/s00535-007-2111-3, 18297430.
66. Berg DJ, Zhang J, Weinstock JV, Ismail HF, Earle KA, Alila H, Pamukcu R, Moore S, Lynch RG. Rapid development of colitis in NSAID-treated IL-10-deficient mice. Gastroenterology 2002, 123:1527-1542. 10.1053/gast.2002.1231527, 12404228.
67. Kühl AA, Pawlowski NN, Grollich K, Loddenkemper C, Zeitz M, Hoffmann JC. Aggravation of intestinal inflammation by depletion/deficiency of gammadelta T cells in different types of IBD animal models. J Leukoc Biol 2007, 81:168-175.
68. Huybers S, Apostolaki M, van der Eerden BC, Kollias G, Naber TH, Bindels RJ, Hoenderop JG. Murine TNF(DeltaARE) Crohn's disease model displays diminished expression of intestinal Ca2+ transporters. Inflamm Bowel Dis 2008, 14:803-811. 10.1002/ibd.20385, 18266230.
69. Hale LP, Greer PK. A novel murine model of inflammatory bowel disease and inflammation-associated colon cancer with ulcerative colitis-like features. PLoS One 2012, 7:e41797-e41808. 10.1371/journal.pone.0041797, 3407062, 22848611.